Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report
Antibody-drug conjugates (ADCs) are a potent class of antineoplastic drugs that deliver cytotoxic agents via targeting with monoclonal antibodies; however, ADCs are associated with high rates of lung toxicities, limiting the therapeutic potential in many patients. We report a case of a patient with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2025-02-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-24-29 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232656965402624 |
|---|---|
| author | Daniel A. Fox Christine Tran Vincent Blot David S. Hong |
| author_facet | Daniel A. Fox Christine Tran Vincent Blot David S. Hong |
| author_sort | Daniel A. Fox |
| collection | DOAJ |
| description | Antibody-drug conjugates (ADCs) are a potent class of antineoplastic drugs that deliver cytotoxic agents via targeting with monoclonal antibodies; however, ADCs are associated with high rates of lung toxicities, limiting the therapeutic potential in many patients. We report a case of a patient with metastatic non–small cell lung cancer taking the ADC telisotuzumab vedotin (Teliso V) plus osimtertinib who developed ADC-induced pneumonitis despite clinical benefit. This patient was able to tolerate treatment for a prolonged period on a novel steroid regimen, using steroids when pneumonitis was asymptomatic but radiologically evident and as a daily suppressant. This treatment strategy may have implications in the broader management of ADC–interstitial lung disease/pneumonitis and underscores its potential mechanisms. |
| format | Article |
| id | doaj-art-8a9fb25e01044c2eb5a4b2b29136ad98 |
| institution | OA Journals |
| issn | 2666-2345 2590-017X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj-art-8a9fb25e01044c2eb5a4b2b29136ad982025-08-20T02:03:07ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2025-02-018210811210.36401/JIPO-24-29i2590-017X-8-2-108Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case ReportDaniel A. Fox0https://orcid.org/0000-0001-7363-5750Christine Tran1Vincent Blot2David S. Hong31 The Margaret M. and Albert B. Alkek Department of Medicine, Baylor College of Medicine, Houston, TX, USA2 Department of Investigational Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA3 Oncology Clinical Development, Abbvie, Seattle, WA, USA2 Department of Investigational Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAntibody-drug conjugates (ADCs) are a potent class of antineoplastic drugs that deliver cytotoxic agents via targeting with monoclonal antibodies; however, ADCs are associated with high rates of lung toxicities, limiting the therapeutic potential in many patients. We report a case of a patient with metastatic non–small cell lung cancer taking the ADC telisotuzumab vedotin (Teliso V) plus osimtertinib who developed ADC-induced pneumonitis despite clinical benefit. This patient was able to tolerate treatment for a prolonged period on a novel steroid regimen, using steroids when pneumonitis was asymptomatic but radiologically evident and as a daily suppressant. This treatment strategy may have implications in the broader management of ADC–interstitial lung disease/pneumonitis and underscores its potential mechanisms.https://jipo.org/doi/pdf/10.36401/JIPO-24-29adcteliso vadc-pneumonitisnsclc |
| spellingShingle | Daniel A. Fox Christine Tran Vincent Blot David S. Hong Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report Journal of Immunotherapy and Precision Oncology adc teliso v adc-pneumonitis nsclc |
| title | Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report |
| title_full | Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report |
| title_fullStr | Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report |
| title_full_unstemmed | Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report |
| title_short | Treatment of c-MET Antibody-Drug Conjugate Asymptomatic Pneumonitis with a Novel Steroid Regimen in Non–Small Cell Lung Cancer: A Case Report |
| title_sort | treatment of c met antibody drug conjugate asymptomatic pneumonitis with a novel steroid regimen in non small cell lung cancer a case report |
| topic | adc teliso v adc-pneumonitis nsclc |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-24-29 |
| work_keys_str_mv | AT danielafox treatmentofcmetantibodydrugconjugateasymptomaticpneumonitiswithanovelsteroidregimeninnonsmallcelllungcanceracasereport AT christinetran treatmentofcmetantibodydrugconjugateasymptomaticpneumonitiswithanovelsteroidregimeninnonsmallcelllungcanceracasereport AT vincentblot treatmentofcmetantibodydrugconjugateasymptomaticpneumonitiswithanovelsteroidregimeninnonsmallcelllungcanceracasereport AT davidshong treatmentofcmetantibodydrugconjugateasymptomaticpneumonitiswithanovelsteroidregimeninnonsmallcelllungcanceracasereport |